GlassScriptPhysician profile
Christine Engle
NPI 1710512207
$9,573.42
in general payments reported to CMS, 2019-2025
55 companies · $3,997 in 2025
The $3,997 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $690 · 2023: $1,506 · 2024: $2,904 · 2025: $3,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,045 · Long Term Medical Supply Or Device Loan: $2,164 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,045.12 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,919.30 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $592.31 | 2021-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $526.63 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $427.43 | 2022-2025 | |
| Janssen Biotech, INC. | $378.57 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $365.65 | 2022-2025 | |
| Daiichi Sankyo INC. | $361.02 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Ipsen Biopharmaceuticals, INC | $324.59 | 2024-2025 | Onivyde, Somatuline Depot |
| Eisai INC. | $219.00 | 2021-2025 | |
| Seagen INC. | $216.13 | 2021-2023 | Padcev, Tukysa |
| Genzyme Corporation | $197.62 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $190.69 | 2021-2025 | Keytruda, Reblozyl, Welireg |
| Gilead Sciences, INC. | $189.38 | 2022-2025 | Trodelvy |
| Exelixis INC. | $170.88 | 2021-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $170.08 | 2021-2025 | Zejula, Jemperli |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $162.45 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Adaptive Biotechnologies Corporation | $131.17 | 2024-2025 | Clonoseq |
| Amgen INC. | $125.80 | 2021-2023 | Kyprolis |
| Astellas Pharma US INC | $117.19 | 2024-2025 | Vyloy, Xospata, Xtandi |
| Springworks Therapeutics, INC. | $115.20 | 2024-2025 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $100.80 | 2024-2025 | Fruzaqla, Iclusig |
| Genentech USA, INC. | $99.16 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Alexion Pharmaceuticals, INC. | $98.72 | 2022-2025 | Ultomiris |
| Caris Mpi, INC. | $97.53 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $93.48 | 2025 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $88.95 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Deciphera Pharmaceuticals INC. | $80.36 | 2023-2025 | Qinlock, Romvimza |
| Tactile Systems Technology INC | $80.02 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $69.67 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $60.34 | 2023-2024 | Fotivda |
| Pharmaessentia USA Corporation | $59.73 | 2023-2025 | Besremi |
| Celgene Corporation | $55.55 | 2023-2025 | Opdualag, Pomalyst |
| Puma Biotechnology, INC. | $54.30 | 2024-2025 | |
| Blueprint Medicines Corporation | $52.19 | 2024-2025 | Ayvakit |
| Sumitomo Pharma America, INC. | $51.38 | 2023-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $46.04 | 2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $44.82 | 2025 | Monoferric |
| Cardinal Health 414 LLC | $44.33 | 2023 | |
| Lilly USA, LLC | $40.72 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Geron Corporation | $34.24 | 2025 | Rytelo |
| Morphosys, US INC. | $31.84 | 2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.41 | 2021 | |
| Stryker Corporation | $26.01 | 2025 | Optablate |
| Mayne Pharma Commercial LLC | $25.55 | 2022 | |
| Servier Pharmaceuticals LLC | $24.96 | 2025 | |
| Tersera Therapeutics LLC | $23.27 | 2023 | Quzyttir |
| Jazz Pharmaceuticals INC. | $21.12 | 2021 | |
| Adc Therapeutics America, INC. | $20.95 | 2023 | |
| Emd Serono, INC. | $20.19 | 2022 | |
| Acrotech Biopharma INC. | $19.89 | 2025 | Beleodaq |
| Recordati_rare_diseases_inc. | $17.52 | 2025 | Enjaymo |
| Alnylam Pharmaceuticals INC. | $16.82 | 2025 | Givlaari |
| Novo Nordisk INC | $15.84 | 2022 | |
| Tempus Ai, INC | $13.72 | 2024 | |
| Foundation Medicine, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.